Search

Prednisolone

Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.

Galantamine

It also acts as an allosteric modulator of the nicotinic receptor, giving its dual mechanism of action clinical significance. … [L13571] It is therefore not considered to be a disease-modifying drug.

Nicaraven

Human interferon beta

Human interferon beta is a polypeptide used in the management of relapsing forms of Multiple Sclerosis (MS), and was initially approved by the FDA in 1992. … It is therefore a potential drug candidate for SARS-CoV-2 based on viral genetic similarity.[A191733,L12012]

Trilaciclib

[L31828] CDK4 and CDK6 inhibitors have been investigated since the mid 1990s for their use in tumorigenesis and chemotherapy.[A229323] Trilaciclib was first described in the literature in 2016. … Trilaciclib, or G1T28, is a CDK4 and CDK6 inhibitor, indicated to reduce the incidence of chemotherapy induced myelosuppression in patients before topotecan-containing or platinum and etoposide-containing

Methoxamine

An alpha-adrenergic agonist that causes prolonged peripheral vasoconstriction. It has little if any direct effect on the central nervous system.

Ethyl biscoumacetate

Ethyl biscoumacetate is a courmarin that is used as an anticoagulant. It has actions similar to those of Warfarin. (From Martindale, The Extra Pharmacopoeia, 30th ed, p226)

DG051

DG051 is designed to decrease risk of heart attack by decreasing the production of leukotriene B4 (LTB4), an end product of the leukotriene pathway and a potent promoter of inflammation. … DG051 is a novel small-molecule inhibitor of leukotriene A4 hydrolase (LTA4H), the protein made by one of the genes in the leukotriene pathway that has been shown to link to risk of heart attack.

Piperacetazine

Piperacetazine was an antipsychotic.

Miocamycin

or as an alternative to erythromycin treatment [A176170]. … Miocamycin is a macrolide type antimicrobial [A176170]. This drug may be marketed in Japan for clinical use as it is listed in the Japanese pharmacopeia [L5737].